Fewer than one in five large Irish businesses have a female board member - below the EU average, new research by Grant Thornton for International Women’s Day tomorrow reveals.
Dublin: 07.03.2014 04.42PM
Medical-devices firm Biotrin has announced the creation of 40 high-end jobs as it invests in a new R&D project in Dublin.
Biotrin, which is owned by Italian Diagnostic company Diasorin, is a leading developer and manufacturer of diagnostic platform technology.
Its new project in Dublin, which is supported by the Irish Government through IDA Ireland, will involve the development of automated molecular diagnostics platform technology and assay reagents for the detection of target DNA and RNA in infectious diseases. It will be based on a new molecular diagnostics technology called loop-mediated isothermal amplification (LAMP).
The venture establishes the Dublin site as Diasorin’s corporate headquarters for molecular diagnostics R&D and will bring the total job number at the facility to more than 100 people.
Ireland attractive to medical-device firms
Announcing the jobs today, Minister for Enterprise, Trade and Innovation Batt O’Keeffe TD, said the investment demonstrates Ireland's attractiveness for leading-edge medical device investments.
“The development of new diagnostic technologies is the type of high-end activity the Government is eager to support as part of our efforts to build the ‘smart’ economy and innovation island.
“Ireland has a strong cluster of firms in the life-science sector, with eight of the Top 10 pharmaceutical and 15 of the Top 20 medical-devices companies based here. The 40 new jobs will add to our reputation as a global leader for life science firms,” O'Keeffe added.
Diasorin CEO Dr Carlo Rosa said the decision to locate the company’s new project in Ireland was based on the country’s “strong” reputation as an RD&I location and on the success of Biotrin’s existing operation here.
“This project is a key element of Diasorin’s, Biotrin’s parent company, RD&I strategy underpinning developments in automation and molecular diagnostics. Automated molecular diagnostics is a key part of Diasorin’s corporate strategy and we look forward to further developing our operations in Ireland as a vital part of this strategy,” he said.
“Biotrin’s investment adds to Ireland’s reputation as a global hub for the life-sciences sector. R&D expansions such as this embed existing operations and pave the way for future investment and job creation,” added IDA Ireland CEO Barry O’Leary.
Article courtesy of Businessandleadership.com